Real-world Dosing Patterns of Rivaroxaban in the United States

Inclusion Criteria: * NVAF (non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with International Classification of Disease ICD-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion * Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics * CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline period * Evidence of continuous enrollment in MarketScan during 180 days before the date of the first prescription of rivaroxaban Exclusion Criteria: * Patients \<18 years of age * Patients with valvular AF (atrial fibrillation) * Pregnancy * Malignant cancers * Transient cause of AF * Patients with VTE (Venous thromboembolism), pulmonary embolism or DVT (Deep Vein Thrombosis) * Patients with major surgery defined as hip or knee replacement * Prescriptions of OACs (Oral anticoagulants) (apixaban,warfarin, dabigatran, rivaroxaban) before index date * Prescription of more than one OAC on the index date